International healthcare holding · Delaware, USA
Building a vertically integrated healthcare platform across the United States and Mexico: diagnostics, distribution, pharmacy, hospital care and public procurement, owned and operated as one ecosystem.
PeopleInnovationInvestmentImpact
What we do
Aivital Health Capital Inc. is an international holding company that acquires, owns, manages and invests in healthcare businesses, medical technology, pharmaceutical distribution, medical equipment and healthcare infrastructure in the United States, Mexico and international markets.
We bring together companies with real operations, physical assets and their own cash flow, and arrange them into a single value chain. The result is a platform with access to the two most relevant healthcare markets in North America.
We identify and acquire operating healthcare companies in Mexico and the United States: equipment and drug distribution, laboratories, imaging, pharmacies, hospitals and a public tender channel.
We consolidate capabilities into one chain: diagnostics and laboratory, distribution, pharmacy retail, hospital care and government procurement.
We finance growth through Series B shares and a fractional economic participation token, distributing consolidated free cash flow.
The ecosystem
Each company holds a specific position in the ecosystem. Together they cover healthcare from diagnosis to public procurement in Mexico and the United States.
Stage 1
3 reference laboratories and 1 imaging center
Medical Tech Biotecnología
Stage 2
Medical equipment, drugs and pharmaceuticals in Mexico and Texas
Multiequipos y Medicamentos
Enzem Medical
Stage 3
Pharmacy network and a hospital as the clinical anchor
Farmacias Punto Médico
Punto Médico Hospital
Stage 4
Federal government tender channel
Multimed
Target portfolio
Distribution · Mexico
Distribution · Texas, USA
Diagnostics · Mexico
Point of care · Mexico
Point of care · Mexico
Public procurement · Mexico
About portfolio information. This site describes the activity, strategic role and integration of the holding's target companies. It does not present revenue, EBITDA, valuations or projected financials for those companies. Operating financial data will be provided exclusively during due diligence to accredited and qualified investors, under a confidentiality agreement.
Acquisition thesis
The thesis rests on companies that already operate, with physical assets and recurring demand. It is not a bet on a single asset: it is staged vertical integration, where each acquisition feeds the next.
Consumption of medicines, diagnostics, equipment and hospital infrastructure responds to health needs, not discretionary spending cycles. That brings stability to the ecosystem's cash flow.
Mexican operations combined with a U.S. platform in Texas make it possible to supply, distribute and invoice on both sides of the border.
When the laboratory, distributor, pharmacy and hospital belong to the same group, the margin a third party used to capture stays inside the ecosystem and becomes distributable cash flow.
Federal tender capability opens a volume channel for the group's own inventory, through healthcare sector supply contracts.
The pharmacy model already operates 3 locations and is designed to scale to 200, making retail the platform's most replicable growth engine.
Series B with a preferred return sets the order of distribution: operations first, then treasury reserve, then the investor's target return, and finally the shareholders' remainder.
Investment platform · Series B
The holding issues Series B shares with a preferred return and offers them to accredited investors through an economic participation token. Each token represents a fractional interest in one Series B share, backed by a special purpose vehicle (SPV) that holds the shares and receives the cash flows from acquisitions.
Represents a fractional interest in Series B shares of Aivital Health Capital Inc. It grants no corporate control: it grants an economic right to the preferred distribution and to the remainder attributable to Series B.
An issuing vehicle holds the Series B shares and concentrates the cash flows from acquisitions. The token is backed by that vehicle, which is the investor's legal counterparty.
Token supply is fixed and released in phases tied to the closing of each acquisition. The offer remains open only to accredited and qualified investors after KYC/AML.
| Issuer | Aivital Health Capital Inc., a corporation incorporated in Delaware, USA. |
|---|---|
| Share class | Series B shares, entitled to a preferred return within the distribution waterfall. |
| Target annual return | 25% annual target on Series B shares (not guaranteed). |
| Distribution frequency | Monthly at approx. 1.88% or quarterly at approx. 5.70%, equivalent to the 25% annual target. |
| Token unit | 1 token = fractional economic participation in 1 Series B share. |
| Supply | Fixed supply, issued in phases tied to the closing of each acquisition. |
| Vehicle | SPV holding the Series B shares and the cash flows from acquisitions. |
| Technical standard | ERC-20 token. |
| Investor registry | Mandatory KYC/AML and whitelist; lock-up and vesting periods. |
| Reporting | Audited quarterly reports. |
| Secondary market | Planned for later roadmap phases, subject to regulatory compliance. |
| Eligible investors | Accredited and qualified investors only. No unregistered public offering. |
Closing the purchase of the ecosystem's target companies.
Equipment and installed capacity for clinical operations.
Growth toward the 200-location Punto Médico goal.
Operating float for public procurement processes (Multimed).
Token platform, KYC/AML, audit and legal structure.
Allocations are target percentages of capital raised and may be adjusted according to the closing schedule of each acquisition.
Distribution waterfall
The group's consolidated free cash flow is distributed in a predetermined order. Series B receives its preferred return before any remainder is distributed to shareholders.
Operating expenses and the administrative structure of the holding and operating companies are covered first.
Treasury is then reserved and a fund is set aside to maintain laboratory, imaging, pharmacy and hospital assets.
The next tranche goes to the Series B preferred return, up to the 25% annual target. This return is a target, not a guarantee.
Once the first three tiers are covered, the remainder is distributed between Series A and Series B shareholders under the terms of the share certificates.
Sources of return
The Series B return is funded by the consolidated free cash flow of the acquired companies, not by contributions from new investors.
Compliance
Tokenization is subject to applicable regulation in Mexico (Fintech Law and CNBV guidelines) and to U.S. securities regulation. The offer is directed exclusively to accredited and qualified investors, with no unregistered public offering and mandatory KYC/AML.
Risk factors
Growth roadmap
The plan advances in phases: first the legal, accounting and compliance structure; then the initial Series B round; then the acquisitions and integrations that build the ecosystem.
Incorporation and organization of the holding's legal, accounting and compliance structure, plus design of the token and issuing vehicle.
Seed capital raise and closing of the initial Series B round for accredited and qualified investors.
Acquisition of Multiequipos y Medicamentos (Mexico) and Enzem Medical (Texas, USA): the group's distribution arms and its access to the U.S. market.
Integration of Medical Tech Biotecnología (3 reference labs, 1 imaging center) and consolidation of the 3 Punto Médico pharmacies.
Activation of the federal tender channel with Multimed and integration of Punto Médico Hospital as the ecosystem's clinical anchor.
Scaling the pharmacy network to 200 locations, external audit, quarterly reporting and opening of the token's secondary market.
Phases describe the holding's planned execution sequence and may be adjusted as each closing progresses.
Leadership
Aivital Health Capital Inc. is led by its founding shareholders, who hold the legal representation and operation of the holding.
President & CEO
Authorized representative of the holding, responsible for acquisition strategy, investor relations and the Series B capital structure.
jaime.lopez@aivitalhealthcapital.comChief Operating Officer
Responsible for group operations, integration of acquired companies and coordination of the laboratory, distribution, pharmacy and hospital value chain.
alfredo.moreno@aivitalhealthcapital.comInvestors
Access to Series B documentation is granted to accredited and qualified investors after the identification process (KYC/AML). Send your request and the team will respond directly.
